Bjerkholt Eric's Form 4 filing
Mirum Pharmaceuticals, Inc.MIRM · filed Sep 12, 2025
- Accession no.
- 0001415889-25-024462
- Filed
- Sep 12, 2025
- Trade date
- Sep 11-12, 2025
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $728.0K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Bjerkholt EricCIK 0001197350 | Officer (CHIEF FINANCIAL OFFICER) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 11, 2025 | Common Stock | MOption exerciseAcquired | +18,333 | –F1 | – | 49,523 | Direct | |
| Sep 12, 2025 | Common Stock | SSaleDisposed | −9,578 | $76.01 | −$728,023.78 | 39,945 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 11, 2025 | Common Stock | MOption exerciseDisposed | −18,333 | $0.00 | $0 | 18,333 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Each restricted stock unit represents a contingent right to receive one share of common stock (or its cash equivalent, at the discretion of the Issuer).
Referenced by the price of 1 transaction in Table I.